Paper24639005
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
Costabel U and 13 others. Adv Ther, 2014. Cited by 107 papers, by iCite.
Cite this record
ConductScience Library. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Papers, record 24639005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24639005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug-Related Side Effects and Adverse Reactions | Major topic |
| Idiopathic Pulmonary Fibrosis | Major topic |
| Pyridones | Major topic |
| Tumor Necrosis Factor-alpha | Major topic |
| Anti-Inflammatory Agents, Non-Steroidal | |
| Disease Management | |
| Disease-Free Survival | |
| Humans | |
| Respiratory Function Tests |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18387510 | Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. | Int Immunopharmacol | 2008 | https://conductscience.org/library/papers/18387510 | PubMed |
| 2 | 11923553 | Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. | Thorax | 2002 | https://conductscience.org/library/papers/11923553 | PubMed |
| 3 | 15665326 | Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2005 | https://conductscience.org/library/papers/15665326 | PubMed |
| 4 | 16844727 | Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. | Thorax | 2006 | https://conductscience.org/library/papers/16844727 | PubMed |
| 5 | 17585107 | Acute exacerbations of idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2007 | https://conductscience.org/library/papers/17585107 | PubMed |
| 6 | 20935110 | Clinical course and prediction of survival in idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/20935110 | PubMed |
| 7 | 19328861 | Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. | Pulm Pharmacol Ther | 2009 | https://conductscience.org/library/papers/19328861 | PubMed |
| 8 | 20050822 | Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. | Expert Opin Investig Drugs | 2010 | https://conductscience.org/library/papers/20050822 | PubMed |
| 9 | 23204124 | Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. | Eur Respir Rev | 2012 | https://conductscience.org/library/papers/23204124 | PubMed |
| 10 | 21571362 | Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. | Lancet | 2011 | https://conductscience.org/library/papers/21571362 | PubMed |
| 11 | 21471066 | An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/21471066 | PubMed |
| 12 | 12098599 | Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. | Eur J Pharmacol | 2002 | https://conductscience.org/library/papers/12098599 | PubMed |
| 13 | 19996196 | Pirfenidone in idiopathic pulmonary fibrosis. | Eur Respir J | 2010 | https://conductscience.org/library/papers/19996196 | PubMed |
| 14 | 19345567 | Epidemiology of interstitial lung diseases in Greece. | Respir Med | 2009 | https://conductscience.org/library/papers/19345567 | PubMed |
| 15 | 18093617 | Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. | Life Sci | 2008 | https://conductscience.org/library/papers/18093617 | PubMed |
| 16 | 22798316 | Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. | Am J Respir Crit Care Med | 2012 | https://conductscience.org/library/papers/22798316 | PubMed |
| 17 | 23056564 | Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. | PLoS One | 2012 | https://conductscience.org/library/papers/23056564 | PubMed |
| 18 | 21525528 | The rising incidence of idiopathic pulmonary fibrosis in the U.K. | Thorax | 2011 | https://conductscience.org/library/papers/21525528 | PubMed |
| 19 | 21632796 | Antifibrotic activities of pirfenidone in animal models. | Eur Respir Rev | 2011 | https://conductscience.org/library/papers/21632796 | PubMed |
| 20 | 12693805 | Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. | Respir Med | 2003 | https://conductscience.org/library/papers/12693805 | PubMed |
Cited by66
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42797420 | Development and Evaluation of a Novel Inhalable Liposomal Powder Co-Encapsulating ASSNAC and Pirfenidone via Spray Freeze-Drying for Targeted Pulmonary Fibrosis Therapy. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797420 | PubMed |
| 42794585 | A Comparative Assessment of the Antifibrotic Effect of Nintedanib Administered via a Medicated Diet or Oral Gavage in a Rat Model of Bleomycin-Induced Pulmonary Fibrosis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794585 | PubMed |
| 42760377 | Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42760377 | PubMed |
| 42563128 | Pharmacokinetics and Safety of Nerandomilast in Healthy Volunteers. | Eur J Drug Metab Pharmacokinet | 2026 | https://conductscience.org/library/papers/42563128 | PubMed |
| 41756284 | Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis. | Front Immunol | 2026 | https://conductscience.org/library/papers/41756284 | PubMed |
| 40843770 | Pirfenidone in Skin Fibrosis and Scarring: From Bench Insights to Clinical Data. | Med Sci (Basel) | 2025 | https://conductscience.org/library/papers/40843770 | PubMed |
| 40402087 | Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial. | Liver Int | 2025 | https://conductscience.org/library/papers/40402087 | PubMed |
| 40356972 | Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40356972 | PubMed |
| 39459489 | Exploring the Role of Hemogram-Derived Ratios and Liver Fibrosis Scores in Pulmonary Fibrosis. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39459489 | PubMed |
| 38967367 | Pirfenidone use in fibrotic diseases: What do we know so far? | Immun Inflamm Dis | 2024 | https://conductscience.org/library/papers/38967367 | PubMed |
| 37892651 | Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease. | J Clin Med | 2023 | https://conductscience.org/library/papers/37892651 | PubMed |
| 37853864 | A Case of Pirfenidone-Induced Photosensitive Drug Eruption. | Ann Dermatol | 2023 | https://conductscience.org/library/papers/37853864 | PubMed |
| 36735694 | Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. | PLoS One | 2023 | https://conductscience.org/library/papers/36735694 | PubMed |
| 36703754 | Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36703754 | PubMed |
| 36674976 | Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36674976 | PubMed |
| 36551989 | Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience. | Biomedicines | 2022 | https://conductscience.org/library/papers/36551989 | PubMed |
| 35996614 | Double Lung Transplantation for Idiopathic Pulmonary Fibrosis in a Patient with a History of Liver Transplantation and Prolonged Journey for Disease-Specific Antifibrotic Therapy. | Case Rep Pulmonol | 2022 | https://conductscience.org/library/papers/35996614 | PubMed |
| 35923422 | Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes. | ERJ Open Res | 2022 | https://conductscience.org/library/papers/35923422 | PubMed |
| 35721111 | Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35721111 | PubMed |
| 35568881 | Behavioural and psychological patterns of patients with idiopathic pulmonary fibrosis: a prospective study. | Respir Res | 2022 | https://conductscience.org/library/papers/35568881 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24639005
GET https://conductscience.org/api/papers/v1/24639005/references?page=2